BioInvent International (OMXS:BINV) announced today that the first patient has been treated in a phase II study of the drug candidate BI-505, developed for the treatment of multiple myeloma. The study is conducted in patients with asymptomatic myeloma (called "smoldering multiple myeloma"). Smoldering myeloma patients have not developed symptoms of disease and the condition can be detected only in laboratory tests. The current study involves up to 10 patients and evaluates disease activity following treatment with BI-505. Secondary objectives include safety, pharmacokinetics and assessment of biomarkers.
Cristina Glad, CEO of BioInvent, commented: "BI-505 is one example of BioInvent's capability to initiate in-house clinical projects, based on our own F.I.R.S.T™ technology and biological expertise. The first clinical study of BI-505 achieved our goals. The candidate drug was well tolerated and indicated therapeutic effect, since seven of a total of 29 patients with advanced multiple myeloma demonstrated stable disease for at least two months. The start of this phase II study is another important step forward for BI-505 and we believe that BI-505 has the potential to address a major unmet need in a broad population of patients."
Researchers find the effect of pesticides on increased cancer risk is comparable to smoking for some cancers